Abstract
It has been reported that a high plasmatic concentration of interleukin-6 (IL-6) is correlated to a lack of response to immunotherapy in several malignancies, suggesting that IL-6 was either a marker of tumour aggressiveness or had only a predictive value of response to immunotherapy. To discriminate between these two possibilities, a retrospective study was performed in a series of 19 patients with metastatic renal cell carcinoma who did not respond to IL-2/IFNalpha/5-FU treatment. Serum levels of IL-6, C-reactive Protein (CRP), soluble IL-2-receptor (sIL-2R), M-CSF and neopterin were assayed before treatment. IL-6 showed a significant correlation with patients median survival time (P < 0.016), suggesting that serum concentration of IL-6 before treatment is a marker of tumour aggressiveness rather than a predictive parameter for an immunological response.
MeSH terms
-
Adult
-
Aged
-
Antimetabolites, Antineoplastic / therapeutic use
-
Biomarkers
-
Biopterins / analogs & derivatives
-
Biopterins / blood
-
C-Reactive Protein / analysis
-
Carcinoma, Renal Cell / blood*
-
Carcinoma, Renal Cell / drug therapy
-
Carcinoma, Renal Cell / mortality
-
Carcinoma, Renal Cell / therapy
-
Combined Modality Therapy
-
Female
-
Fluorouracil / therapeutic use
-
Humans
-
Immunologic Factors / therapeutic use
-
Immunotherapy
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use
-
Interleukin-6 / blood*
-
Kidney Neoplasms / blood*
-
Kidney Neoplasms / drug therapy
-
Kidney Neoplasms / mortality
-
Kidney Neoplasms / therapy
-
Macrophage Colony-Stimulating Factor / blood
-
Male
-
Middle Aged
-
Neoplasm Metastasis
-
Neopterin
-
Prognosis
-
Receptors, Interleukin-2 / blood
-
Recombinant Proteins
-
Retrospective Studies
-
Survival Analysis
Substances
-
Antimetabolites, Antineoplastic
-
Biomarkers
-
Immunologic Factors
-
Interferon alpha-2
-
Interferon-alpha
-
Interleukin-6
-
Receptors, Interleukin-2
-
Recombinant Proteins
-
Biopterins
-
Neopterin
-
Macrophage Colony-Stimulating Factor
-
C-Reactive Protein
-
Fluorouracil